Aberdeen Group plc Raises Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Aberdeen Group plc increased its stock holdings in Ultragenyx Pharmaceutical Inc. by 51.0% in the first quarter, owning a total of 478,904 shares valued at approximately $17.3 million.
• Other institutional investors have also boosted their positions in Ultragenyx, with GAMMA Investing LLC growing its stake by 76.2% during the same period.
• Ultragenyx reported a quarterly revenue of $166.50 million, exceeding analysts' estimates, along with an EPS of ($1.17), surpassing forecasts by $0.10.

Aberdeen Group plc grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 51.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 478,904 shares of the biopharmaceutical company's stock after acquiring an additional 161,779 shares during the period. Aberdeen Group plc owned 0.51% of Ultragenyx Pharmaceutical worth $17,341,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System raised its holdings in shares of Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock valued at $3,284,000 after acquiring an additional 268 shares in the last quarter. GAMMA Investing LLC raised its stake in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Xponance Inc. lifted its position in Ultragenyx Pharmaceutical by 2.8% during the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after purchasing an additional 347 shares during the last quarter. BOKF NA increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC raised its position in shares of Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after buying an additional 395 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.26 on Friday, reaching $29.78. 1,267,904 shares of the company traded hands, compared to its average volume of 1,298,327. The firm has a fifty day simple moving average of $31.85 and a 200-day simple moving average of $35.89. The company has a market cap of $2.87 billion, a P/E ratio of -5.39 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company's quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on RARE shares. Cantor Fitzgerald cut their target price on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Guggenheim reiterated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Morgan Stanley dropped their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.